Exosomes in bladder cancer: novel biomarkers and targets.
Biomarker
Bladder cancer
Clinical application
Exosome
Function
Journal
Journal of Zhejiang University. Science. B
ISSN: 1862-1783
Titre abrégé: J Zhejiang Univ Sci B
Pays: China
ID NLM: 101236535
Informations de publication
Date de publication:
15 May 2021
15 May 2021
Historique:
entrez:
11
5
2021
pubmed:
12
5
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Exosomes are nanometer-sized vesicles that contain various types of biologically active components, including proteins, nucleic acids, carbohydrates, and lipids, which vary with the type and physiological state of the cell. In recent years, several studies have showed that exosomes can provide new non-invasive diagnostic and prognostic biomarkers in patients affected by cancers, including bladder cancer (BC), and the lipid bilayer membrane structure makes exosomes as promising delivery vehicles for therapeutic applications. Exosomes have the characteristics of high abundance, high stability, tissue specificity, and wide distribution in body fluids, and are secreted as various types by cells in different states, thereby possessing great potential as biomarkers for BC. Herein, we briefly summarize the functions and roles of exosomes in the occurrence and development of BC and the current progress of research on exosomes in BC, while focusing on potential clinical applications of the diagnosis, treatment, and prognosis of BC.
Identifiants
pubmed: 33973417
pii: 1673-1581(2021)05-0341-07
doi: 10.1631/jzus.B2000711
pmc: PMC8110466
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
341-347Références
Nat Rev Drug Discov. 2013 May;12(5):347-57
pubmed: 23584393
Asian Pac J Cancer Prev. 2019 Jul 01;20(7):2219-2224
pubmed: 31350988
Cell Death Dis. 2017 Oct 5;8(10):e3066
pubmed: 28981096
Onco Targets Ther. 2017 May 22;10:2665-2673
pubmed: 28579804
Cancer Manag Res. 2018 Nov 26;10:6357-6365
pubmed: 30568497
J Urol. 2016 May;195(5):1331-1339
pubmed: 26714199
Cancer Manag Res. 2018 Nov 05;10:5373-5381
pubmed: 30464633
Mol Cancer Res. 2018 Jul;16(7):1196-1204
pubmed: 29636362
Urol Oncol. 2015 Dec;33(12):505.e1-7
pubmed: 26282902
Annu Rev Biochem. 2019 Jun 20;88:487-514
pubmed: 31220978
Mol Cancer. 2018 Oct 3;17(1):143
pubmed: 30285771
J Clin Invest. 2020 Jan 2;130(1):404-421
pubmed: 31593555
J Cell Mol Med. 2019 Feb;23(2):1396-1405
pubmed: 30467945
J Urol. 2014 Aug;192(2):297-8
pubmed: 24837807
Minerva Urol Nefrol. 2020 Apr;72(2):207-213
pubmed: 31144487
Int J Oncol. 2020 Jan;56(1):151-164
pubmed: 31814034
Mol Ther Nucleic Acids. 2019 Dec 6;18:787-800
pubmed: 31734559
Mol Cancer. 2017 Aug 25;16(1):143
pubmed: 28841829
Oncogenesis. 2015 Aug 17;4:e163
pubmed: 26280654
Urol Oncol. 2017 Dec;35(12):674.e19-674.e24
pubmed: 28888400
Clin Cancer Res. 2018 Dec 15;24(24):6319-6330
pubmed: 30305293
Cancer Med. 2020 Aug;9(16):6009-6019
pubmed: 32627968
EXCLI J. 2020 Mar 04;19:301-310
pubmed: 32231490
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Med Sci Monit. 2018 Dec 21;24:9307-9316
pubmed: 30576305
J Clin Oncol. 2019 Jun 20;37(18):1547-1557
pubmed: 31059311
Int J Biol Markers. 2019 Jun;34(2):101-107
pubmed: 30862241
J Biol Chem. 2019 Mar 1;294(9):3207-3218
pubmed: 30593508
Mol Diagn Ther. 2019 Oct;23(5):579-601
pubmed: 31325035
Lancet Oncol. 2018 Dec;19(12):e683-e695
pubmed: 30507435
Cancer Sci. 2019 Jul;110(7):2119-2132
pubmed: 31141251
Mol Cancer. 2018 Sep 29;17(1):142
pubmed: 30268126
FASEB J. 2020 Sep;34(9):12177-12196
pubmed: 32716585
Cell Biol Int. 2020 Apr;44(4):958-965
pubmed: 31872468
Cells. 2020 Jun 07;9(6):
pubmed: 32517366
PLoS One. 2016 Jan 22;11(1):e0147236
pubmed: 26800519
J Urol. 2014 Aug;192(2):583-92
pubmed: 24530986
Trends Mol Med. 2010 Sep;16(9):398-406
pubmed: 20667783